<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02180295</url>
  </required_header>
  <id_info>
    <org_study_id>V212-014</org_study_id>
    <secondary_id>2014-001030-29</secondary_id>
    <nct_id>NCT02180295</nct_id>
  </id_info>
  <brief_title>A Lot-to-Lot Consistency Study to Evaluate Safety, Tolerability, and Immunogenicity of Inactivated Varicella Zoster Virus (VZV) Vaccine in Healthy Adults (V212-014)</brief_title>
  <official_title>A Phase III, Double-Blind, Lot-To-Lot Consistency Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of V212 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the consistency of 3 lots of inactivated VZV vaccine for safety,&#xD;
      tolerability, and immunogenicity in healthy adults. The primary hypothesis of the study is&#xD;
      that the 3 lots of inactivated vaccine will demonstrate similar immunogenicity at 28 days&#xD;
      after the fourth dose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Titer of VZV Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Antibody Titers</measure>
    <time_frame>28 days postdose 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with a Serious Adverse Experience</measure>
    <time_frame>Up to 28 days postdose 4</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Herpes Zoster</condition>
  <arm_group>
    <arm_group_label>V212 Lot 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 7.5 Units/0.5 mL subcutaneous injection administered in a 4-dose regimen given approximately 30 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V212 Lot 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 7.5 Units/0.5 mL subcutaneous injection administered in a 4-dose regimen given approximately 30 days apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V212 Lot 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Approximately 7.5 Units/0.5 mL subcutaneous injection administered in a 4-dose regimen given approximately 30 days apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V212 Lot 1</intervention_name>
    <description>Inactivated Varicella Zoster Virus vaccine</description>
    <arm_group_label>V212 Lot 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V212 Lot 2</intervention_name>
    <description>Inactivated Varicella Zoster Virus vaccine</description>
    <arm_group_label>V212 Lot 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>V212 Lot 3</intervention_name>
    <description>Inactivated Varicella Zoster Virus vaccine</description>
    <arm_group_label>V212 Lot 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Afebrile (&lt;=100.4 °F [&lt;=38.0 °C]) oral or equivalent on Day 1 before the first&#xD;
             vaccination&#xD;
&#xD;
          -  Any underlying chronic illness that is not in stable condition&#xD;
&#xD;
          -  History of varicella, antibodies to VZV, or residence (for &gt;=30 years) in a country&#xD;
             with endemic VZV infection&#xD;
&#xD;
          -  Female participants of childbearing potential must have a negative pregnancy test. A&#xD;
             female not of reproductive potential has reached natural menopause, or is 6-weeks&#xD;
             postsurgical bilateral oophorectomy and/or hysterectomy or bilateral tubal ligation&#xD;
&#xD;
          -  Male, or female of childbearing potential who agrees to remain abstinent or use 2&#xD;
             acceptable methods of birth control from 2 weeks before enrollment to 6 months after&#xD;
             the last study vaccination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of allergic reaction to any vaccine component, or an&#xD;
             anaphylactic/anaphylactoid reaction to neomycin (not including contact dermatitis to&#xD;
             neomycin)&#xD;
&#xD;
          -  Prior history of herpes zoster&#xD;
&#xD;
          -  History of receipt or expects to receive any varicella or zoster vaccine during the&#xD;
             study period&#xD;
&#xD;
          -  Is pregnant or breastfeeding, or expects to conceive from 2 weeks before enrollment to&#xD;
             6 months after the last study vaccination&#xD;
&#xD;
          -  Has received a live virus vaccine or is scheduled to receive any live virus vaccine&#xD;
             from 4 weeks before the first dose of study vaccination and throughout the study&#xD;
&#xD;
          -  Has received any inactivated vaccine or is scheduled to receive any inactivated&#xD;
             vaccine from 7 days before to 7 days after any study vaccination&#xD;
&#xD;
          -  Received immunoglobulin or any blood products or is scheduled to receive them from 5&#xD;
             months before the first dose of study vaccination and throughout the study&#xD;
&#xD;
          -  Has participated in an investigational drug or vaccine study within 30 days before&#xD;
             enrollment&#xD;
&#xD;
          -  Has any acute illness or significant underlying illness that may interfere with&#xD;
             interpretation of the study&#xD;
&#xD;
          -  Receiving immunosuppressive therapy (including systemic corticosteroid doses exceeding&#xD;
             physiological replacement doses within 14 days prior to the first vaccination), except&#xD;
             topical, ophthalmic, or inhaled corticosteroids or intra-articular or soft-tissue&#xD;
             injections of steroids&#xD;
&#xD;
          -  Has known or suspected immune dysfunction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>July 1, 2014</study_first_submitted>
  <study_first_submitted_qc>July 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2014</study_first_posted>
  <last_update_submitted>August 11, 2015</last_update_submitted>
  <last_update_submitted_qc>August 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

